InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NSPR
Bullish
high confidence
Mentioned
$NSPR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRBullishHigh
01

Why it matters

The FDA approval is a primary catalyst that could significantly expand revenue, while the earnings show a narrowing loss and reduced cash runway.

02

Market read

First‑report of a regulatory approval for a micro‑cap med‑tech firm, likely to move the stock on news flow.

03

What to watch

Potential delays in commercial launch and competition from other carotid stent technologies.

Relevance 7/10Novelty 8/10Timing: today after filing
AlphAI · Earnings readNSPR · Q3 2026 · ended 2026-09-30

InspireMD Q3 2026 revenue fell 11.1% to $2,242,000 on the U.S. recall, with gross margin at 10.7% and a $9,762,000 net loss, while FDA approval of CGuard Prime for TCAR was announced

↓Weak quarter

Total revenue fell 11.1% year over year to $2,242,000 and U.S. revenue fell to $32,000 from $497,000, which the company links to the May 2026 recall. Gross margin was 10.7% of revenue against 34.2%, and the net loss was $9,762,000. Cash and marketable securities were $19,246,000 at September 30, 2026, against $54,211,000 at December 31, 2025. International revenue grew 9.1%, and the TCAR approval is a positive development, but the reported figures are weak.

Revenue
$2,242,000
decrease of $281,000, or 11.1% y/y
International revenue (Q3 2026)
$2,210,000
increase of $184,000, or 9.1% y/y
Gross margin · GAAP
10.7% of revenue
EPS · GAAP
$(0.12)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue (Q3 2026)GAAP$2,242,000–decrease of $281,000, or 11.1%
International revenue (Q3 2026)GAAP$2,210,000–increase of $184,000, or 9.1%
U.S. revenue (Q3 2026)GAAP$32,000––
Total revenue (nine months ended Sept 30, 2026)GAAP$7,411,000–increase of $1,581,000, or 27.1%
International revenue (nine months ended Sept 30, 2026)GAAP$6,552,000–increase of $1,273,000, or 24.1%
U.S. revenue (nine months ended Sept 30, 2026)GAAP$859,000––
Cost of revenues (Q3 2026)GAAP$2,002,000––
Cost of revenues (nine months ended Sept 30, 2026)GAAP$7,258,000––
Gross profit (Q3 2026)GAAP$240,000––
Gross margin (Q3 2026, gross profit as % of revenue)GAAP10.7% of revenue––
Gross profit (nine months ended Sept 30, 2026)GAAP$153,000––
Gross margin (nine months ended Sept 30, 2026, gross profit as % of revenue)GAAP2.1% of revenue––
Research and development (Q3 2026)GAAP$3,273,000––
Research and development (nine months ended Sept 30, 2026)GAAP$12,331,000––
Selling and marketing (Q3 2026)GAAP$2,394,000––
Selling and marketing (nine months ended Sept 30, 2026)GAAP$12,795,000––
General and administrative (Q3 2026)GAAP$3,452,000––
General and administrative (nine months ended Sept 30, 2026)GAAP$12,329,000––
Restructuring and other (Q3 2026)GAAP$1,074,000––
Restructuring and other (nine months ended Sept 30, 2026)GAAP$1,074,000––
Total operating expenses (Q3 2026)GAAP$10,193,000–decrease of $3,722,000, or 26.7%
Total operating expenses (nine months ended Sept 30, 2026)GAAP$38,529,000–decrease of $470,000, or 1.2%
Loss from operations (Q3 2026)GAAP−$9.95M––
Loss from operations (nine months ended Sept 30, 2026)GAAP−$38.38M––
Financial income, net (Q3 2026)GAAP$191,000––
Financial income, net (nine months ended Sept 30, 2026)GAAP$601,000––
Net loss (Q3 2026)GAAP$9,762,000––
Net loss (nine months ended Sept 30, 2026)GAAP$37,775,000––
Net loss per share, basic and diluted (Q3 2026)GAAP$(0.12)––
Net loss per share, basic and diluted (nine months ended Sept 30, 2026)GAAP$(0.45)––
Cash and cash equivalents and marketable securities (as of Sept 30, 2026)GAAP$19,246,000––
Total assets (as of Sept 30, 2026)GAAP$33.57M––
Total equity (as of Sept 30, 2026)GAAP$21.75M––

Segments

SegmentRevenueq/qy/y
International revenue (Q3 2026)The filing reports international revenue growth. The company attributes the lower gross margin partly to mix within international revenue toward countries with a lower average sales price.$2,210,000–increase of $184,000, or 9.1%
U.S. revenue (Q3 2026)According to the company, the U.S. sales comparison reflects the impact of the voluntary recall of the delivery system of the CGuard Prime for CAS in May 2026. Prior-year U.S. revenue was $497,000.$32,000––
International revenue (nine months ended Sept 30, 2026)The filing reports growth in international revenue for the nine months. Prior-year international revenue for the period was $5,279,000.$6,552,000–increase of $1,273,000, or 24.1%
U.S. revenue (nine months ended Sept 30, 2026)The filing states that the gross profit decline for the nine months reflects the impact of the mix of revenue due to the U.S. recall action. Prior-year U.S. revenue for the period was $551,000.$859,000––

Capital returns

  • The filing reports no share repurchases or dividends.
  • Common shares issued and outstanding were 47,119,438 at September 30, 2026, against 43,532,281 at December 31, 2025, as printed on the balance sheet.
  • Additional paid-in capital was $361,814 thousand at September 30, 2026, against $357,489 thousand at December 31, 2025.

What drove it

  • FDA approval of CGuard Prime for TCAR procedures was announced. The company expects to commence U.S. sales promptly in the fourth quarter of 2026, and it cites support from CGUARDIANS II pivotal trial data showing 100% acute device success and zero death, stroke, myocardial infarction or stent thrombosis reported at 30 days.
  • International revenue grew 9.1% in Q3 2026 to $2,210,000, and 24.1% for the nine months to $6,552,000.
  • Total operating expenses fell 26.7% in Q3 2026 to $10,193,000. The company reports $1,074,000 in restructuring expenses and related termination costs tied to a workforce reduction within that quarter.
  • The company states that the Q3 2026 gross profit decline reflects the impact of the U.S. recall action and the mix within international revenue toward countries with a lower average sales price.

Concerns

  • Total revenue fell 11.1% in Q3 2026 to $2,242,000, and U.S. revenue fell to $32,000 from $497,000. The company attributes the U.S. decline to the May 2026 voluntary recall of the CGuard Prime for CAS delivery system.
  • Gross margin was 10.7% of revenue in Q3 2026, against 34.2% in Q3 2025. For the nine months it was 2.1% of revenue, against 25.2%.
  • Cost of revenues rose to $2,002,000 from $1,659,000 in Q3 while revenue fell.
  • The net loss was $9,762,000 for Q3 2026 and $37,775,000 for the nine months.
  • Cash and cash equivalents and marketable securities fell to $19,246,000 from $54,211,000 at December 31, 2025. Total equity fell to $21,752 thousand from $55,201 thousand.
  • The forward-looking statements section refers to substantial doubt about the company's ability to continue as a going concern and to the need to raise additional capital, which may be dilutive.

What to watch

  • Commencement of U.S. sales of CGuard Prime for TCAR, which the company expects promptly in Q4 2026.
  • The PMA supplement for the enhanced CGuard Prime for CAS, which the company expects to submit to the FDA in December 2026, with potential re-launch in the first half of 2027.
  • The CGUARDIANS III pivotal trial of the SwitchGuard neuroprotection system, which is enrolling.
  • The planned introduction of a proprietary micro puncture kit.
  • Gross margin recovery and the recall-related costs described in the risk factors, including refunds, inventory write-offs and remediation costs.
  • Liquidity and any capital raise, given cash of $19,246,000 and the going concern language in the filing.
  • The company's investor conference call at 4:30 pm ET on November 12, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $19,246 thousand at September 30, 2026, against $8,939 thousand at December 31, 2025. Marketable securities were nil at September 30, 2026, against $45,272 thousand at December 31, 2025.
  • The filing prints cash and cash equivalents and marketable securities of $19,246,000 at September 30, 2026, compared with $54,211,000 as of December 31, 2025.
  • Total assets were $33,568 thousand at September 30, 2026, against $69,404 thousand at December 31, 2025. Total liabilities were $11,816 thousand, against $14,203 thousand.
  • Total equity was $21,752 thousand at September 30, 2026, against $55,201 thousand at December 31, 2025. The accumulated deficit was $(340,067) thousand, against $(302,292) thousand.
  • Operating cash flow, free cash flow and debt are not printed in the release. The forward-looking statements section refers to the company's history of recurring losses and negative operating cash flows and to substantial doubt about its ability to continue as a going concern.

Analysis

InspireMD reported third-quarter 2026 total revenue of $2,242,000, down 11.1% from $2,523,000 a year earlier. The company ties the decline to the U.S. market, where revenue was $32,000 against $497,000, and states that the comparison reflects the voluntary recall of the CGuard Prime for CAS delivery system in May 2026. International revenue grew 9.1% to $2,210,000, and for the nine months international revenue rose 24.1% to $6,552,000. Total revenue for the nine months was $7,411,000, up 27.1%, but the release gives no U.S. percentage change for the period.

Profitability weakened sharply. Gross profit was $240,000 in Q3 2026, or 10.7% of revenue, against $864,000, or 34.2%, a year earlier. Cost of revenues rose to $2,002,000 from $1,659,000. The company links the gross profit decline to the U.S. recall action and to the mix within international revenue toward countries with a lower average sales price. For the nine months gross margin was 2.1% of revenue against 25.2%.

Operating expenses fell 26.7% to $10,193,000 in Q3 2026, driven by lower selling and marketing ($2,394,000 against $4,392,000) and general and administrative expenses ($3,452,000 against $5,888,000). The quarter also includes $1,074,000 of restructuring expenses and related termination costs tied to a workforce reduction. Research and development rose to $3,273,000 from $3,635,000 in Q3 but was higher for the nine months at $12,331,000 against $11,528,000. Loss from operations was $(9,953) thousand against $(13,051) thousand, and the net loss was $9,762,000, or $0.12 per share, against $12,708,000, or $0.17.

On the balance sheet, cash and cash equivalents were $19,246 thousand at September 30, 2026, and marketable securities were nil, against $45,272 thousand at December 31, 2025. Total equity declined to $21,752 thousand from $55,201 thousand. Shares outstanding rose to 47,119,438 from 43,532,281. The release does not print operating or free cash flow, and the forward-looking statements refer to recurring losses, negative operating cash flows and substantial doubt about the company's ability to continue as a going concern.

The regulatory news is the main positive. The FDA approved CGuard Prime for TCAR procedures, which the company says expands its addressable U.S. market by over 35,000 procedures annually, and it expects U.S. sales to commence promptly in Q4 2026. The company gives no quantified revenue or margin guidance for that launch. The PMA supplement for CGuard Prime for CAS is expected in December 2026, with a potential re-launch in the first half of 2027.

Management, verbatim

FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-generation carotid implant that incorporates the latest carotid technology into a rapidly growing TCAR market,

Marvin Slosman, Chief Executive Officer

Not in the filing

stated, not guessed
  • No previous-period outlook was supplied, so no guidance comparison is available.
  • Operating cash flow, free cash flow and capital expenditure are not printed.
  • Debt or borrowings are not printed.
  • Prior-year figure for restructuring and other is not printed; the table shows a dash for Q3 2025 and nine months 2025.
  • Percentage changes for U.S. revenue are not printed for either period.
  • Percentage change for the nine-month loss from operations, net loss and gross profit is not printed.
  • Percentage change for gross profit and gross margin, year over year, is not printed.
  • Quarter-over-quarter comparisons are not printed.
  • Share price reaction and analyst expectations are not in the documents.
  • Revenue guidance, gross margin guidance and operating expense guidance are not printed.
  • Non-GAAP measures are not printed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

InspireMD (Nasdaq: NSPR) filed a Form 8‑K reporting its Q3 2026 results and FDA clearance for a new TCAR stent system.

Company-level read

Ticker impact

$NSPRBullishHigh confidence
Context

InspireMD disclosed FDA approval of its CGuard® Prime for TCAR and released Q3 2026 financial results, including a net loss of $9.76M and cash of $19.2M.

Expected impact

likely upward pressure as investors price in the new market opportunity from the TCAR approval

Evidence & confidence

Regulatory approval is a material catalyst for a micro‑cap medical device company; the market typically reacts positively on first‑day news.

Market effects

Strengthens the carotid intervention segment and may boost peer valuations in the med‑tech space.

U.S. market focus as the approval targets U.S. TCAR procedures.

Limited to niche vascular device market; minimal broader market effect.

Counterpoint

The company still reports a net loss and low cash, raising concerns about execution risk and funding needs.

Key entities

  • InspireMD, Inc.

    Medical device maker specializing in carotid stent systems.

  • FDA

    U.S. Food and Drug Administration that granted the TCAR indication.

Every NSPR earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

$NSPRMed

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.